IDH2 and acute myeloid leukemia: Advances in cancer genetics have revealed that antibodies against the mutant IDH protein have been detected in various human malignancies, including glioma [73], cholangiocarcinoma [74], acute myeloid leukemia (AML) [75], and chondrosarcoma, such as CCS and DDCS [76,77].